
---
title: '呼吸道合胞病毒疫苗和单抗最新研究进展（10）'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=953575'
author: 科学网
comments: false
date: Mon, 29 Aug 2022 09:06:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=953575'
---

<div>   
<h1 style="margin-top:0;margin-right:0;margin-bottom:14px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><strong style="font-size: 16px;"><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 24px"></span></strong><span style="font-size: 36px;"><strong><span style="color: #231F20; letter-spacing: 1px; background: #FFFFFF; font-size: 36px; font-family: Shaker2Lancet-Bold;">呼吸道合胞病毒预防制剂曙光在前:　<br></span></strong></span></h1><p style="margin: 0 0 24px;padding: 0"><span style="font-size: 36px;"><strong><span style="color: #231F20; letter-spacing: 1px; background: #FFFFFF; font-size: 36px; font-family: Shaker2Lancet-Bold;">疫苗和单克隆抗体百舸争流</span></strong></span></p><p style="margin: 0 0 24px;padding: 0"><span style="font-size: 36px;"><strong><span style="color: #069A2E; letter-spacing: 0px; background: #FFFFFF; font-family: "Microsoft YaHei UI";"><strong style="overflow-wrap: break-word; color: rgb(51, 51, 51); font-family: Tahoma, Helvetica, SimSun, sans-serif, Hei; font-size: 14px; white-space: normal;"><span style="overflow-wrap: break-word; font-family: "Microsoft YaHei UI"; color: #069A2E; letter-spacing: 0px; font-size: 24px;">前言：</span></strong></span></strong></span></p><p style="margin: 0 0 24px;padding: 0"><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">　　新冠病毒大流行的将近３年，也是世界疫苗行业突飞猛进、疫苗研发技术日新月异、硕果</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">累累的３年。疫苗制备的多种技术途径都得到深度开发，若干种新兴的技术途径如mRNA疫苗获得了空前的成功，在世界各地大行其道，在多种传染病以及癌症和其他慢性病的防治领域都在不断开花结果。</span></strong></p><p style="margin: 0 0 24px;padding: 0"><strong><span style="font-family: 'Microsoft YaHei UI';color: #069A2E;letter-spacing: 0;font-size: 24px;background: #FFFFFF">　　</span></strong><strong><span style="text-decoration: underline; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">呼吸道合胞病毒（</span></strong><strong><span style="text-decoration: underline; font-family: Shaker2Lancet-Bold; color: #231F20; letter-spacing: 1px; font-size: 24px; background: #FFFFFF;">Respiratory syncytial virus，</span></strong><strong><span style="text-decoration: underline; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">RSV</span></strong><strong><span style="text-decoration: underline; color: #231F20; letter-spacing: 1px; font-size: 24px; background: #FFFFFF; font-family: Shaker2Lancet-Bold;">）</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">是一种历史悠久、危害极大的传染病，其疫苗的研发已经有四十年的历史， 但最初开发的疫苗反而会引发</span></strong><strong><span style="text-decoration: underline; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">疫苗相关性呼吸道疾病（VAERD，Vaccine-associated enhanced respiratory diseases</span></strong><strong><span style="letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">）</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">，即未接触过</span></strong><strong><span style="text-decoration: underline; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">RSV</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">的儿童在接种了疫苗后，如果再接触到该病毒反而会发生更严重的</span></strong><strong><span style="text-decoration: underline; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">RSV</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">疾病。诸如此类的问题导致针对</span></strong><strong><span style="text-decoration: underline; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">RSV</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">的疫苗一直未能上市。乘新冠病毒疫苗大跃进的东风，已赚得盆满钵满的疫苗巨头如</span></strong><strong><span style="text-decoration: underline; color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">辉瑞（Pfizer)</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">、</span></strong><strong><span style="text-decoration: underline; color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">莫德纳（Moderna</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">）和</span></strong><strong><span style="text-decoration: underline; color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">葛兰素史克(GSK)</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">等目前都在</span></strong><strong><span style="text-decoration: underline; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">RSV</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">的疫苗开发上快马加鞭，有望在较短时间内取得重大突破。</span></strong></p><p style="margin: 0 0 24px;padding: 0"><strong><span style="font-family: 'Microsoft YaHei UI';letter-spacing: 0;font-size: 24px;background: #FFFFFF">　　</span></strong><strong><span style="text-decoration: underline; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">RSV</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">疫苗和单克隆抗体研究领域来自世界各地的顶级研究人员（约５０人）近期联名在国际著名专业杂志《</span></strong><strong><span style="color: #FF0000; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">Lancet</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";"> Infect Dis》上发表综述论文，介绍相关最新研究进展（见</span></strong><strong><span style="color: #222222; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">参考文献</span></strong><strong><span style="color: #069A2E; letter-spacing: 0px; font-size: 24px; background: #FFFFFF; font-family: "Microsoft YaHei UI";">），本博客将分数次介绍此综述的主要内容。</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><span style="font-family: Tahoma;color: #333333;letter-spacing: 0;font-size: 21px">目录：</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><span style="font-family: Tahoma;color: #333333;letter-spacing: 0;font-size: 21px">摘要</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><span style="font-family: Tahoma;color: #333333;letter-spacing: 0;font-size: 21px"><span style="font-family:Tahoma">一</span>.　前言</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><span style="font-family: Tahoma;color: #333333;letter-spacing: 0;font-size: 21px"><span style="font-family:Tahoma">二</span>.　方法</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><span style="font-family: Tahoma;color: #333333;letter-spacing: 0;font-size: 21px"><span style="font-family:Tahoma">三</span>.　教训（Lessons learned）</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><span style="font-family: Tahoma;color: #333333;letter-spacing: 0;font-size: 21px"><span style="font-family:Tahoma">四</span>.　活的减毒疫苗（liv</span><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">eattenuated vaccines</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">，</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">LAVs </span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">五</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">.</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">　嵌合疫苗（</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">Chimeric </span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">六</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">.</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">　亚单位疫苗（</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">Subunit</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">七</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">.</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">　基于颗粒的疫苗（</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">Particle-based </span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">八</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">.</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">　核酸疫苗（</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">Nucleic acid</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">九</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">.</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">　重组载体疫苗（</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">Recombinant vectors</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">十</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">.</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">　单克隆抗体（</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">MAbs</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">十一</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px">.</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">　讨论</span></strong><strong><span style="font-family: Calibri;color: #333333;letter-spacing: 0;font-size: 21px"> </span></strong></p><p style="margin: 0 0 24px;padding: 0"><strong><span style="font-family: SimSun;color: #231F20;letter-spacing: 0;font-size: 29px;background: #FFFFFF"><span style="font-family:SimSun">六</span><span style="font-family:Shaker2Lancet-Bold">.</span>　</span></strong><strong><span style="color: #231F20; letter-spacing: 0px; font-size: 29px; background: #FFFFFF; font-family: Shaker2Lancet-Bold;">亚单位疫苗（</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 29px;background: #FFFFFF">Subunit</span></strong><strong><span style="color: #231F20; letter-spacing: 0px; font-size: 29px; background: #FFFFFF; font-family: Shaker2Lancet-Bold;">）</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">亚</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">单位</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">疫苗</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">是基于蛋白质的</span>;这种方法在从未接触过 RSV的儿童中应避免使用，因为已知</span><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">福尔马林灭活的</span></strong><strong><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;">RSV</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">会</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">增强呼吸</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">道</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">疾病</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">,对没有被活病毒感染过的人它确实会<span style="font-family:ScalaLancetPro">增强呼吸道疾病</span>,这是人们最担心的。由于一种</span><strong><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;">post-F </span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">（后融合蛋白）</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">亚单位候选<span style="font-family:ScalaLancetPro">疫苗第</span>3期临床试验<span style="font-family:ScalaLancetPro">失败</span>,有５种候选疫苗选用了</span><strong><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #0000FF; font-size: 19px;">pre-F</span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #0000FF; font-size: 19px; font-family: ScalaLancetPro;">（前融合蛋白）</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">作为疫苗抗原。有8种亚单位候选疫苗正在开发中，适用于两种<span style="font-family:ScalaLancetPro">不同的目标人群</span>:孕妇和老年人。我们首先讨论使用融合蛋白作<span style="font-family:ScalaLancetPro">抗原的候选疫苗</span>,随后再讨论使用非融合蛋白作抗原的候选疫苗。</span>　　</p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><strong><span style="font-family: ScalaLancetPro;line-height: 200%;color: #231F20;font-size: 19px">DS-Cav1</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">是一种使用稳定的</span> </span><strong><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #0000FF; font-size: 19px;">pre-F </span></strong><strong><span style="text-decoration: underline; line-height: 200%; color: #0000FF; font-size: 19px; font-family: ScalaLancetPro;">（前融合蛋白</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">）的亚单位疫苗，由</span><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;"><span style="font-family:ScalaLancetPro">美国国家卫生研究院（</span>NIH)</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">和</span><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;"><span style="font-family:ScalaLancetPro">美国国家过敏和传染病研究所</span>(NIAID</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">)开发。DS-Cav1的一期临床研究结果为基于结构的疫苗设计提供了</span><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;"><span style="font-family:ScalaLancetPro">概念证明</span>(proof-of-concept</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">)。接种疫苗可使血清中和活性提高十倍以上，并可在<span style="font-family:ScalaLancetPro">整个</span>RSV季节持续保持。另外两种候选疫苗</span><span style=";font-family:SimSun;line-height:200%;color:#231F20;font-size:19px">也</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">使用稳定的</span> pre-F 蛋白作为疫苗抗原。RSV</span>　<span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">pre-F (PF-06928316)含<span style="font-family:ScalaLancetPro">稳定的二价</span>(亚型 A和B)的pre-F，不含佐剂。RSV</span>　<span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">preF的<span style="font-family:ScalaLancetPro">一项</span>2期临床试验在未怀孕的患者中进行，<span style="font-family:ScalaLancetPro">与白喉类毒素和无细胞百日咳疫苗联合使用，相对于</span>RSV</span>　<span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">preF单独使用显示了安全性和非劣效性。而<span style="font-family:ScalaLancetPro">抗百日咳反应较差</span>(与单独使用白喉类毒素和无细胞百日咳疫苗相比，联合使用时百日咳抗原的几何平均浓度仅<span style="font-family:ScalaLancetPro">在</span>0.59到0.8之间)，但这些发现的临床意义仍不清楚，并在根据年龄对结果进行调整后没有差异。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">在孕妇中开展的代号为MATISSE的3期临床<span style="font-family:ScalaLancetPro">试验于</span>2020年开始，预计将于2023年即试验的第四季度</span><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;"><span style="font-family:ScalaLancetPro">揭盲（</span>unblinded</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">）。人体<span style="font-family:ScalaLancetPro">挑战试验显示</span>RSV pre-F对RSV感染的有效性为75%，并确定了用于孕妇的候选疫苗的剂量和配方。使用同一候选疫苗的代号为RENOIR的 3期临床<span style="font-family:ScalaLancetPro">试验已于</span>2021年秋季开始，包括3万名健康和高危的老年人。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">另一种</span>pre-F亚单位疫苗，RSVpreF3，正在进行3期临床试验，其中无佐剂的疫苗GSK3888550A是给孕产妇接种以<span style="font-family:ScalaLancetPro">保护婴儿</span>(GRACE试验)，含AS01佐剂的GSK3844766A是用于<span style="font-family:ScalaLancetPro">保护老年人群。</span>2022年2月18日，由于出现安全信号，上述用于孕产妇的候选疫苗的开发工作暂停。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">在1 - 2期临床试验中，用于老年人的候选疫苗<span style="font-family:ScalaLancetPro">是安全的，诱导的</span>pre-F IgG和IgA抗体大约增加了10倍，试验包括48名18-40岁的成年人和1005名年龄在60-80岁的成年人。针对老年患者的候选疫苗<span style="font-family:ScalaLancetPro">的</span>3期临床试验中期分析显示对RSV下呼吸道感染有效(试验登录号NCT04886596)。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">对于孕产妇候选疫苗<span style="font-family:ScalaLancetPro">，在未怀孕的健康女性</span>(n=502)中进行的1期和2期研究显示，针对RSV  A和B亚型毒株的<span style="font-family:ScalaLancetPro">中和抗体滴度在接种后</span>1周增加了14倍，91天后仍<span style="font-family:ScalaLancetPro">保持了</span>6倍或更多的增加。<span style="font-family:ScalaLancetPro">在孕产妇候选疫苗的</span>3期临床研究中，由于接种者在分娩<span style="font-family:ScalaLancetPro">后</span>6个月内对RSV A和RSV B亚型的抗体仍保持较高水平，证明<span style="font-family:ScalaLancetPro">免疫应答是持久的。</span>RSV</span>　<span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">preF孕产妇疫苗预计在2024年注册，RSV</span>　<span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">preF老年疫苗和两种RSV pre-F3候选疫苗预计在2025年注册，根据临床试验注册的惯例，都会在第三期临床试验<span style="font-family:ScalaLancetPro">完成日期后</span>1年内获得注册。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">目前有三种使用</span><strong><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #0000FF; font-size: 19px;"><span style="font-family:ScalaLancetPro">非</span>F病毒抗原</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的基于病毒蛋白的候选疫苗正在临床开发中。其中</span><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">第一种候选疫苗</span></strong><strong><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;">BARS13</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">是<span style="font-family:ScalaLancetPro">利用</span>RSV 的G蛋白作为抗原并利用</span><span style="font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px; text-decoration: underline;">环孢霉素A ( cyclosporine A，CSA</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">)作为免疫抑制剂来<span style="font-family:ScalaLancetPro">诱导调节性</span>T细胞。BARS13在1期临床试验中显示具有安全性和免疫原性，目前正<span style="font-family:ScalaLancetPro">处于</span>2期临床试验中。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">其中</span><strong><span style="text-decoration: underline; line-height: 200%; color: #231F20; font-size: 19px; font-family: ScalaLancetPro;">第二种候选疫苗</span></strong><strong><span style="text-decoration: underline; font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px;">DPX-RSV</span></strong><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px"><span style="font-family:ScalaLancetPro">利用</span>RSV-A-SHe蛋白的</span><span style="font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px; text-decoration: underline;">外结构域（ectodomain</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">）作为疫苗抗原，在便于储存的脂包油传递平台上配制，可使抗原和佐剂的作用时间<span style="font-family:ScalaLancetPro">延长。提出的对抗这种抗原的作用机制是产生</span>SHe特异性抗体，通过增强肺泡巨噬细胞的吞噬作用<span style="font-family:ScalaLancetPro">来促进</span>RSV感染细胞</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">的清除。DPX-RSV在第一期人体临床试验中首次在50 - 64岁的成年人中显示了安全性和免疫</span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">原性。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">其中</span><span style="font-family: ScalaLancetPro; line-height: 200%; color: #231F20; font-size: 19px; text-decoration: underline;"><strong>第三种候选疫苗VN-0200</strong></span><span style=";font-family:ScalaLancetPro;line-height:200%;color:#231F20;font-size:19px">以VAGA-9001a为抗原，以MABH-9002b为佐剂(1期临床试验)。我们目前无法确定VAGA-9001a的生物学背景。</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:43px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">（未完</span></strong><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">待续）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 24px">参考文献：</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><em><span style="font-family: Shaker2Lancet-Italic;color: #006F3C;letter-spacing: 0;font-size: 20px">Natalie I Mazur,</span></em><em>　</em><em><span style="font-family: Shaker2Lancet-Italic;color: #006F3C;letter-spacing: 0;font-size: 20px">et al., </span></em><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 20px">Respiratory syncytial virus prevention within reach:</span></strong><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 20px"> the vaccine and monoclonal antibody landscape, </span></strong><em><span style="font-family: Shaker2Lancet-Bold;color: #FF0000;letter-spacing: 0;font-size: 20px">Lancet Infect Dis</span></em><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 20px"><span style="font-family:Shaker2Lancet-Bold">，</span> Published online August 8, 2022， </span></strong><span style="font-family: Tahoma;color: #505050;letter-spacing: 0;font-size: 20px">DOI: </span><a href="https://doi.org/10.1016/S1473-3099(22)00291-2" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 20px">https://doi.org/10.1016/S1473-3099(22)00291-2</span></a><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 20px">，</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00291-2/fulltext" target="_blank"><span style="text-decoration: underline; font-family: Shaker2Lancet-Bold; color: #6666CC; letter-spacing: 0px; font-size: 20px;">https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00291-2/fulltext</span></a><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 20px">.</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Shaker2Lancet-Bold;color: #231F20;letter-spacing: 0;font-size: 24px">相关博文：</span></strong><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1350903" target="_blank"></a></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1350903" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=953575" title alt="image.png" referrerpolicy="no-referrer"><span style="color: #6666CC; letter-spacing: 0px; font-size: 19px; font-family: Tahoma;">呼吸道合胞病毒疫苗和单抗最新研究进展（１）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 20px"> 2022-08-12</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1350986" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=953573" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>2）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-13</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1351276" target="_blank"></a><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=953572" title alt="image.png" referrerpolicy="no-referrer"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1351276" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>3）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-15</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1351490" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>4）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-17</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1351871" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>5）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-20</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1352158" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>6）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-22</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1352448" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=953570" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>7）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-24</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1352713" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=953568" title alt="image.png" referrerpolicy="no-referrer"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>8）</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2022-08-26</span></p><p style="line-height: 200%;"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=953566" title alt="image.png" referrerpolicy="no-referrer"><a href="https://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1352981" target="_blank"><strong><span style="text-decoration: underline; font-family: Tahoma; line-height: 200%; color: #6666CC; letter-spacing: 0px; font-size: 19px; background: #FFFFFF;"><span style="font-family:Tahoma">呼吸道合胞病毒疫苗和单抗最新研究进展（</span>9）</span></strong></a><span style="font-family: Tahoma;line-height: 200%;color: #666666;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> 2022-08-28</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-347754-1353081.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-347754-1353081.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1352981.html" target="_black">呼吸道合胞病毒疫苗和单抗最新研究进展（9）</a><br>                    <!--大赛结束-->
                                        
  
</div>
            